To provide an overview of the efficacy and adverse effects associated with once-daily administration of aminoglycosides.
DATA SOURCES:
An extensive MEDLINE search and review of journals was conducted to identify information for this review.
DATA SYNTHESIS:
Aminoglycosides alone or in combination with beta-lactams are commonly used for their activity against gram-negative microorganisms. Numerous studies have been performed comparing efficacy and toxicity of once-daily administration of aminoglycosides with multiple-daily dosing. Two studies have found a significant difference in clinical efficacy between once-daily and multiple-daily dosing of aminoglycosides. Several studies have observed a lower incidence of toxicity with once-daily than multiple-daily dosing, but others have found no difference.
CONCLUSIONS:
Review of the literature suggests that once-daily administration of aminoglycosides may be as safe and effective as multiple-daily dosing regimens for the treatment of certain infections caused by gram-negative bacteria.
Get full access to this article
View all access options for this article.
References
1.
KuninCM. Dosage schedules of antimicrobial agents: A historical review. Rev Infect Dis1981; 3: 4–11.
GerberAU. Comparison of once-daily versus thrice-daily human equivalent dosing of aminoglycosides: Basic considerations and experimental approach. J Drug Dev1988; 1 (suppl 3): 17–23.
4.
VogelmanBGudmundssonSTrunidgeJLeggettJCraigWA. In vivo postantibiotic effect in a thigh infection in neutropenic mice. J Infect Dis1988; 157: 287–98.
5.
SpiveyJM. The postantibiotic effect. Clin Pharm1992; 11: 865–75.
6.
JohnJF. What price success? The continuing saga of the toxic: Therapeutic ratio in the use of aminoglycoside antibiotics. J Infect Dis1988; 158: 1–6.
7.
MooreRDSmithCRLietmanPS. Risk factors for the development of auditory toxicity in patients receiving aminoglycosides. J Infect Dis1984; 149: 23–30.
8.
LernerAMConeLAJansenWReyesMPBlairDCWrightGERandomized, controlled trial of the comparative efficacy, auditory toxicity, and nephrotoxicity of tobramycin and netilmicin. Lancet1983; 1: 1123–5.
9.
BernsteinJMGorseGJLinzmayerMIPegramPSLevinRDBrummettRERelative efficacy and toxicity of netilmicin and tobramycin in oncology patients. Arch Intern Med1986; 146: 2329–34.
10.
FeeWE. Aminoglycoside ototoxicity in the human. Laryngoscope1980; 90 (suppl 24):l–19.
SchentagJJCerraFBPlautME. Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients. Antimicrob Agents Chemother1982; 21: 721–6.
13.
KapusnikJEHackbarthCJChambersHFCarpenterTSandeMA. Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental Pseudomonas pneumonia. J Infect Dis1988; 158: 7–12.
14.
GerberAUFeller-SegessenmannC. In vivo assessment of in vitro killing patterns of Pseudomonas aeruginosa. J Antimicrob Chemother1985; 15: 201–6.
15.
GerberAUCraigWABruggerHPFellerCVastolaAPBrandelJ. Impact of dosing intervals on activity of gentamicin and ticarcillin against Pseudomonas aeruginosa in granulocytopenic mice. J Infect Dis1983; 147: 910–7.
16.
MacKenzieFMGouldIM. The post-antibiotic effect. J Antimicrob Chemother1993; 32: 519–37.
17.
MooreRDSmithCRLietmanPS. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis1984; 149: 443–8.
18.
NoonePParsonTMCPattisonJRSlackRCBGarfield-DaviesDHughesK. Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis. Br Med J1974; 1: 477–81.
19.
MooreRDSmithCR. Lietman PS. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med1984; 77: 657–62.
20.
MooreRDLietmanPSSmithCR. Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis1987; 155: 93–9.
21.
Ba HuyTran PBernardPSchachtJ. Kinetics of gentamicin uptake and release in the rat. J Clin Invest1986; 77: 1492–500.
22.
SilverblattFJKuehnC. Autoradiography of gentamicin uptake by the rat proximal tubule cell. Kidney Int1979; 15: 335–45.
23.
GiulianoRAPaulusGJVerpootenGAPattynVMPolletDENouwenEJRecovery of cortical phospholipidosis and necrosis after acute gentamicin loading in rats. Kidney Int1984; 26: 838–47.
24.
LuftFCKleitSA. Renal parenchymal accumulation of aminoglycoside antibiotics in rats. J Infect Dis1974; 130: 656–9.
25.
De BroeMEPaulusGJVerpootenGARoelsFBuyssensNWedeenREarly effects of gentamicin, tobramycin, and amikacin on the human kidney. Kidney Int1984; 25: 643–52.
26.
GiulianoRAVerpootenGAVerbistLWedeenRPDe BroeME. In vivo uptake kinetics of aminoglycosides in the kidney cortex of rats. J Pharmacol Exp Ther1986; 236: 470–5.
27.
GiulianoRAVerpootenGADe BroeME. The effect of dosing strategy on kidney cortical accumulation of aminoglycosides in rats. Am J Kid Dis1986; 8: 297–303.
28.
ReinerNEBloxhamDDThompsonWL. Nephrotoxicity of gentamicin and tobramycin given once daily or continuously in dogs. J Antimicrob Chemother1978; 4 (suppl A):85–101.
29.
AronoffGRPottratzSTBrierMEWalkerNEFinebergNSGiantMDAminoglycoside accumulation kinetics in rat renal parenchyma. Antimicrob Agents Chemother1983; 23: 74–8.
30.
De BroeMEGiulianoRAVerpootenGA. Choice of drug and dosage regimen. Two important risk factors for aminoglycoside nephrotoxicity. Am J Med1986; 80 (suppl 6B):115–8.
31.
De BroeMEVerbistLVerpootenGA. Influence of dosage schedule on renal cortical accumulation of amikacin and tobramycin in man. J Antimicrob Chemother1991; 27 (suppl C):4l–7.
32.
FramePTPhairJPWatanakunakornCBannisterTWP. Pharmacologic factors associated with gentamicin nephrotoxicity in rabbits. J Infect Dis1977; 135: 952–6.
33.
WoodCANortonDRKohlheppSJKohnenPWPorterGAHoughtonDCThe influence of tobramycin dosage regimens on nephrotoxicity, ototoxicity, and antibacterial efficacy in a rat model of subcutaneous abscess. J Infect Dis1988; 158: 13–22.
34.
BennettWMPlampCEGilbertDNParkerRAPorterGA. The influence of dosage regimen on experimental gentamicin nephrotoxicity: Dissociation of peak serum levels from renal failure. J Infect Dis1979; 140: 576–80.
35.
VerpootenGAGiulianoRAVerbistLEestermansGDe BroeME. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther1989; 45: 22–7.
36.
BrierMEMayerPRBrierRAVisscherDLuftFCAronoffGR. Relationship between rat renal accumulation of gentamicin. tobramycin, and netilmicin and their nephrotoxicities. Antimicrob Agents Chemother1985; 27: 812–6.
37.
PowellSHThompsonWLLutheMASternRCGrossniklausDABloxhamDDOnce-daily vs. continuous aminoglycoside dosing: Efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin. J Infect Dis1983; 147: 918–32.
BeaubienAROrmsbyEBayneACarrierKCrossfieldGDowriesMEvidence that amikacin ototoxicity is related to total perilymph area under the concentration-time curve regardless of concentration. Antimicrob Agents Chemother1991; 35: 1070–4.
40.
FederspilPSch?tzteWTieslerE. Pharmacokinetics and ototoxicity of gentamicin, tobramycin, and amikacin. J Infect Dis1976; 134 (suppl):200–5.
41.
Ba HuyTran PManuelCMeulemansASterkersOAmielC. Pharmacokinetics of gentamicin in perilymph and endolymph of the rat as determined by radioimmunoassay. J Infect Dis1981; 143: 476–86.
42.
ChungMParraviciniLAssaelBMCavannaGRadwanskiESymchowiczS. Comparative pharmacokinetics of aminoglycoside antibiotics in guinea pigs. Anlimicmb Agents Chemother1982; 22: 1017–21.
43.
Ba HuyTran PDeffrennesD. Aminoglycoside ototoxicity; influence of dosage regimen on drug uptake and correlation between membrane binding and some clinical features. Acta Otolaryngol1988; 105: 511–5.
44.
DulonDAranJMZajicGSchachtJ. Comparative uptake of gentamicin, netilmicin, and amikacin in the guinea pig cochlea and vestibule. Antimicroh Agents Chemother1986; 30: 96–100.
45.
ParraviciniLArpiniABamonteFMarzanattiMOnginiE. Comparative ototoxicity of amikacin, gentamicin, netilmicin, and tobramycin in guinea pigs. Toxicol Appl Pharmacol1982; 65: 222–30.
46.
DavisRRBrummettREBendrickTWHimesDL. Dissociation of maximum concentration of kanamycin in plasma and perilymph from ototoxic effect. J Antimicrob Chemother1984; 14: 291–302.
47.
BeaubienARDesjardinsSOrmsbyEBayneACarrierKCauchyMJIncidence of amikacin ototoxicity: A sigmoid function of total drug exposure independent of plasma levels. Am J Otolaryngol1989; 10: 234–43.
48.
BamonteFDionisottiSGambaMOnginiEArpiniAMeloneG. Relation of dosing regimen to aminoglycoside ototoxicity: Evaluation of auditory damage in the guinea pig. Chemotherapy1990; 36: 41–50.
49.
PierreCBlanchetFSetaNChaignePLabarreCSterkersOTolerance of once-daily dosing of netilmicin and teicoplanin, alone or in combination, in healthy volunteers. Clin Pharmacol Ther1988; 44: 458–66.
50.
ProctorLPettyBLietmanPThakorRGlackinRShimizuH. A study of potential vestibulotoxic effects of once daily versus thrice daily administration of tobramycin. Laryngoscope1987; 97: 1443–9.
51.
ViscoliCDudleyMFerreaGBoniLCastagnolaEBarrettaMASerum concentrations and safety of single daily dosing of amikacin in children undergoing bone marrow transplantation. J Antimicrob Chemother1991; 27 (suppl C): 113–20.
52.
KafetzisDASianidouLVlachosEDavrosJBairamisTPapandreouYClinical and pharmacokinetic study of a single daily dose of amikacin in pediatric patients with severe gram-negative infections. J Antimicrob Chemother1991; 27 (suppl C): 105–12.
53.
ViganoAPrincipiNBrivioLTommasiPStasiPVillaAD. Comparison of 5 milligrams of netilmicin per kilogram of body weight once daily versus 2 milligrams per kilogram thrice daily for treatment of gram-negative pyelonephritis in children. Antimicrob Agents Chemother1992; 36: 1499–503.
54.
ShankarASharmaSD. Gentamicin as once-daily dose therapy in recurrent urinary tract infections in children. Curr Ther Res1987; 41: 599–603.
55.
MailerRIsakssonBNilssonLSorenL. A study of amikacin given once versus twice daily in serious infections. J Antimicrob Chemother1988; 22: 75–9.
56.
VanhaeverbeekMSiskaGDouchampsJHerchuelzA. Comparison of the efficacy and safety of amikacin once or twice-a-day in the treatment of severe gram-negative infections in the elderly. Int J Clin Pharmacol Ther Toxicol1993; 31: 153–6.
57.
TulkensPM. Efficacy and safety of aminoglycosides once-a-day: Experimental and clinical data. Stand J Infect Dis1991; 74: 249–57.
58.
PrinsJMBullerHRKuijperEJTangeRASpeelmanP. Once versus thrice daily gentamicin in patients with serious infections. Lancet1993; 341: 335–9.
59.
Ter BraakEWdeVriesPJBouterKPVegtSGVDorresteinGCNortierJWOnce-daily dosing regimen for aminoglycoside plus—lactam combination therapy of serious bacterial infections: Comparative trial with netilmicin plus ceftriaxone. Am J Med1990; 89: 58–66.
60.
de VriesPJVerkooyenRPLeguitPVerbrughHA. Prospective randomized study of once-daily versus thrice-daily netilmicin regimens in patients with intraabdominal infections. Eur J Clin Microb Infect Dis1990; 9: 161–8.
61.
SturmAW. Netilmicin in the treatment of gram-negative bacteremia: Single daily versus multiple daily dosage. J Infect Dis1989; 159: 931–7.
62.
HollenderLFBahniniJDe ManziniNLauWYFanSTHermansyurKA multicentric study of netilmicin once daily versus thrice daily in patients with appendicitis and other intra-abdominal infections. J Antimicrob Chemother1989; 23: 773–83.
63.
NordstromLRingbergHCronbergSTjernstromOWalderM. Does administration of an aminoglycoside in a single daily dose affect its efficacy and toxicity?J Antimicrob Chemother1990; 25: 159–73.
64.
FanSTLauWYTeoh-ChanCHLauKFMauracherEH. Once daily administration of netilmicin compared with thrice daily, both in combination with metronidazole, in gangrenous and perforated appendicitis. J Antimicrob Chemother1988; 22: 69–74.
65.
da CostaMendes PKaufmanL. Amikacin once daily plus metronidazole versus amikacin twice daily plus metronidazole in colorectal surgery. Hepatogastroenterology1992; 39: 350–4.
GiamarellouHYiallourosKPetrikkosGMoschovakisEVavourakiEVoutsinasDComparative kinetics and efficacy of amikacin administered once or twice daily in the treatment of systemic gram-negative infections. J Antimicrob Chemother1991; 27 (suppl C):73–9.
68.
The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and cetazidime for infection in patients with cancer and granulocytopenia. Ann Intent Med1993; 119: 584–93.
69.
RozdzinskiEKernWVReichleAMoritzTSchmeiserTGausWOnce-daily versus thrice-daily dosing of netilmicin in combination with—lactam antibiotics as empirical therapy for febrile neutropenic patients. J Antimicrob Chemother1993; 31: 585–98.
70.
Der AuweraPVMeunierFIbrahimSKaufmanLDerdeMPTulkensPM. Pharmacodynamic parameters and toxicity of netilmicin (6 milligrams/kilogram/day) given once daily or in three divided doses to cancer patients with urinary tract infection. Antimicrob Agents Chemother1991; 35: 640–7.
71.
HansenMAchenFCarstensenCCoolidgeJDahlagerJFrimodt-MollerNOnceversus thrice-daily dosing of netilmicin in febrile immunocompromized patients: A randomized, controlled study of efficacy and safety. J Drug Dev1988; L (suppl 3): 119–24.
72.
HessenMTPitsakisPGLevisonME. Absence of a postantibiotic effect in experimental Pseudomonas endocarditis treated with imipenem, with or without gentamicin. J Infect Dis1988; 158: 542–8.
73.
HessenMTPitsakisPGLevisonME. Postantibiotic effect of penicillin plus gentamicin versus Enterococcus faecalis in vitro and in vivo. Antimicrob Agents Chemother1989; 33: 608–11.
74.
FantinBCarbonC. Importance of the aminoglycoside dosing regimen in the penicillin-netilmicin combination for treatment of Enterococcus faecalis induced experimental endocarditis. Antimicrob Agents Chemother1990; 34: 2387–91.
